All In Biotech

Drug Trial Radar · NCT03456700

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease

Last checked: Nov 20, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

22

Actual

Start

Mar 30, 2018

Primary completion

Jul 31, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.

Conditions

  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma

Interventions

  • AuranofinDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • SirolimusDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Confirmed Tumor Response (Partial Response [PR] or Complete Response [CR] at Least 4 Weeks Apart)Time frame: 1 year 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.